MA41785A - Procédés et compositions pour l'administration intraveineuse de fumarates pour le traitement de maladies neurologiques - Google Patents

Procédés et compositions pour l'administration intraveineuse de fumarates pour le traitement de maladies neurologiques

Info

Publication number
MA41785A
MA41785A MA041785A MA41785A MA41785A MA 41785 A MA41785 A MA 41785A MA 041785 A MA041785 A MA 041785A MA 41785 A MA41785 A MA 41785A MA 41785 A MA41785 A MA 41785A
Authority
MA
Morocco
Prior art keywords
fumarates
compositions
treatment
methods
intravenous administration
Prior art date
Application number
MA041785A
Other languages
English (en)
Inventor
Shyam Karki
Robert Scannevin
Ajay Verma
Fengmei Zheng
Original Assignee
Biogen Ma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Ma Inc filed Critical Biogen Ma Inc
Publication of MA41785A publication Critical patent/MA41785A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/695—Silicon compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Psychology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
MA041785A 2015-03-20 2016-03-17 Procédés et compositions pour l'administration intraveineuse de fumarates pour le traitement de maladies neurologiques MA41785A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562136431P 2015-03-20 2015-03-20

Publications (1)

Publication Number Publication Date
MA41785A true MA41785A (fr) 2018-01-23

Family

ID=55702079

Family Applications (1)

Application Number Title Priority Date Filing Date
MA041785A MA41785A (fr) 2015-03-20 2016-03-17 Procédés et compositions pour l'administration intraveineuse de fumarates pour le traitement de maladies neurologiques

Country Status (15)

Country Link
US (1) US20180289655A1 (fr)
EP (1) EP3270895A2 (fr)
JP (1) JP2018508559A (fr)
KR (1) KR20170138437A (fr)
CN (1) CN107666905A (fr)
AR (1) AR104029A1 (fr)
AU (1) AU2016235743A1 (fr)
CA (1) CA2979544A1 (fr)
EA (1) EA201792076A1 (fr)
HK (1) HK1244680A1 (fr)
IL (1) IL254576A0 (fr)
MA (1) MA41785A (fr)
MX (1) MX2017012239A (fr)
TW (1) TW201642847A (fr)
WO (1) WO2016153957A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202116297A (zh) * 2019-07-03 2021-05-01 西班牙商布爾奴爾法碼有限公司 組合療法之方法、組成物與套組
TW202131914A (zh) 2019-10-30 2021-09-01 西班牙商布爾奴爾法碼有限公司 用於神經疾病或病狀的治療之新治療方案

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4959389A (en) 1987-10-19 1990-09-25 Speiser Peter P Pharmaceutical preparation for the treatment of psoriatic arthritis
DE19721099C2 (de) 1997-05-20 1999-12-02 Fumapharm Ag Muri Verwendung von Fumarsäurederivaten
DK1663197T3 (da) * 2003-09-09 2008-01-07 Fumapharm Ag Anvendelse af fumarsyrederivater til behandling af hjerteinsuffiens og astma
CA2478458A1 (fr) 2004-08-20 2006-02-20 Michael Panzara Traitement de la sclerose en plaques pediatrique
SI1799196T1 (sl) * 2004-10-08 2016-10-28 Forward Pharma A/S Farmacevtski sestavki z nadzorovanim sproščanjem, obsegajoči ester fumarne kisline
EP1940382A2 (fr) 2005-10-07 2008-07-09 Aditech Pharma AB Polytherapie a base d' esters d' acide fumarique pour le traitement de maladies autoimmunes et/ou inflammatoires
US20080089861A1 (en) 2006-07-10 2008-04-17 Went Gregory T Combination therapy for treatment of demyelinating conditions
EP2653873B8 (fr) * 2007-02-08 2022-08-24 Biogen MA Inc. Compositions et leurs utilisations pour le traitement de la Sclérose en plaques
HUE032251T2 (en) * 2007-02-08 2017-09-28 Biogen Ma Inc Neuroprotection in demyelinating diseases
WO2009158432A2 (fr) 2008-06-27 2009-12-30 Amgen Inc. Inhibition de l’ang-2 pour traiter la sclérose en plaques
MX2011001341A (es) 2008-08-19 2011-03-29 Xenoport Inc Prodrogas de metil hidrogeno fumarato, sus composiciones farmaceuticas, y metodos de uso.
EP3318249A1 (fr) 2009-04-29 2018-05-09 Biogen MA Inc. Régimes posoloqiques du fumarate de diméthyle pour le traitement de la sclérose en plaques
DK2533634T3 (en) 2010-02-12 2016-01-25 Biogen Ma Inc NEURO PROTECTIVE demyelinating diseases
JP5072128B2 (ja) * 2011-03-31 2012-11-14 株式会社ワコール カップ部を有する衣類
US20140308244A1 (en) 2011-08-08 2014-10-16 The Board Of Trustees Of The Leland Stanford Junior University Combination Therapy for Treatment of Inflammatory Demyelinating Disease
EP2791181A4 (fr) * 2011-12-16 2015-08-05 Biogen Ma Inc Esters de l'acide fumarique contenant du silicium
US20130158077A1 (en) 2011-12-19 2013-06-20 Ares Trading S.A. Pharmaceutical compositions
CA2862885C (fr) 2012-02-07 2020-06-02 Biogen Ma Inc. Compositions pharmaceutiques contenant du fumarate de dimethyle
US20140057918A1 (en) 2012-08-22 2014-02-27 Xenoport, Inc. Methods of Use for Monomethyl Fumarate and Prodrugs Thereof
AR094277A1 (es) 2012-12-21 2015-07-22 Biogen Idec Inc Derivados de fumarato sustituidos con deuterio
EP3243511B1 (fr) 2012-12-21 2019-03-20 ratiopharm GmbH Promédicaments de monométhylfumarate (mmf)
CN105163730B (zh) 2013-01-08 2018-10-30 帕萨罗杰卡有限公司 用于治疗脱髓鞘疾病的方法和组合物
US10905663B2 (en) 2013-03-05 2021-02-02 The University Of Chicago Treatment of demyelinating disorders
US8669281B1 (en) 2013-03-14 2014-03-11 Alkermes Pharma Ireland Limited Prodrugs of fumarates and their use in treating various diseases
US20150079180A1 (en) * 2013-09-18 2015-03-19 Xenoport, Inc. Nanoparticle compositions of dimethyl fumarate
CN103768045B (zh) * 2013-10-30 2015-10-07 苏州大学附属第一医院 富马酸二甲酯在制备治疗蛛网膜下腔出血后早期脑损伤药物的应用
WO2016074684A1 (fr) * 2014-11-11 2016-05-19 Syddansk Universitet Dérivés d'acide fumarique à usage médical

Also Published As

Publication number Publication date
CN107666905A (zh) 2018-02-06
AR104029A1 (es) 2017-06-21
IL254576A0 (en) 2017-11-30
CA2979544A1 (fr) 2016-09-29
US20180289655A1 (en) 2018-10-11
EP3270895A2 (fr) 2018-01-24
EA201792076A1 (ru) 2018-04-30
MX2017012239A (es) 2018-06-27
JP2018508559A (ja) 2018-03-29
WO2016153957A3 (fr) 2016-11-10
KR20170138437A (ko) 2017-12-15
TW201642847A (zh) 2016-12-16
WO2016153957A2 (fr) 2016-09-29
HK1244680A1 (zh) 2018-08-17
AU2016235743A1 (en) 2017-10-12

Similar Documents

Publication Publication Date Title
IL298690B1 (en) Preparations and methods for suppressing masp-3 for the treatment of various diseases and conditions
EP3630072A4 (fr) Procédés et compositions pour le traitement d'une somnolence excessive
MA51200A (fr) Nouveaux composés et compositions pharmaceutiques associées pour le traitement de maladies
EP3390634A4 (fr) Compositions et méthodes pour le traitement de maladies oculaires
EP3448875A4 (fr) Compositions pour le traitement de maladies
EP3448987A4 (fr) Compositions pour le traitement de maladies
ME03314B (fr) Thérapie basée sur l'arnm pour le traitement des maladies oculaires
EP3481387A4 (fr) Methodes et compositions pour le traitement de troubles épileptiques
EP3389725A4 (fr) Compositions et méthodes pour le traitement de maladies du système nerveux central
EP3341391A4 (fr) Compositions et procédés pour le traitement de la douleur
EP2861246A4 (fr) Compositions et procédés pour l'inhibition de masp-1 et/ou masp-2 et/ou masp-3 pour le traitement de divers troubles et maladies
EP3390642A4 (fr) Compositions et procédés pour le traitement de rétinite pigmentaire 18 et de rétinite pigmentaire 13
EP3352749A4 (fr) Composés et compositions pour le traitement de troubles oculaires
EP3481958A4 (fr) Procédés et compositions de traitement de troubles et de maladies impliquant rdh12
ZA202006234B (en) Compositions and methods for the treatment of neurological diseases
EP2967062A4 (fr) Déséthylhydroxychloroquine pour le traitement de maladies associées avec l'inflammation
EP3634431A4 (fr) Compositions et méthodes thérapeutiques pour le traitement de l'hépatite b
EP3443962A4 (fr) Dérivé de quinoline pour le traitement du cancer de l'estomac
EP3389673A4 (fr) Procédés et compositions pour l'administration de polynucléotides
EP3347010A4 (fr) Synthèse et composition d'agents thérapeutiques photodynamiques pour le traitement ciblé du cancer
EP3400008A4 (fr) Compositions thérapeutiques et méthodes pour le traitement de l'hépatite b
EP3368048A4 (fr) Méthodes et compositions pour le traitement de l'amyloïdose
MA45552A (fr) Compositions destinées au traitement de l'amylose
EP3373922A4 (fr) Compositions et méthodes pour le traitement de l'homocystinurie
EP3364965A4 (fr) Méthodes et compositions pour le traitement de maladies neurodégénératives